To verify the pro‐tumorigenic effects of myCAFs, we first performed survival analyses using a dataset from The Cancer Genome Atlas (TCGA), which contained 252 patients with CSCC.[82] The GSVA score for myCAFs was calculated for each patient with CSCC using the marker gene set (ACTA2, POSTN, ITGB4, and FAP). This evidence concerns the gene POSTN and skin squamous cell carcinoma.